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Immediate surgery in cardiopulmonary bypass 
(CPB) and deep hypothermia was performed. The 
patient was transferred to the operating room di-
rectly from the admission unit, after 66 minutes 
needed for transthoracic echocardiography and 
preoperative laboratory workup. Dabigatran in-
take did not delay any part of cardiosurgical man-
agement. A supracoronary ascending aortic and 
hemiarch replacement procedure was successful-
ly performed. Following CPB cessation, idaruci-
zumab was administered (5 g IV, in 1 infusion of 
5-minute duration). A total of 12 units of plate-
let concentrate and 3 units of fresh frozen plas-
ma were administered in the operating room. The 
control level of dabigatran immediately upon in-
tensive care unit admission was below 32 ng/ml. 
Three units of packed red blood cells were trans-
fused. Moderate perioperative bleeding was ob-
served5 and drainage volumes were low (390 ml 
after 24 hours).
During the postoperative course, the patient 
required diuretic treatment and intensive pulmo-
nary rehabilitation. The postoperative course was 
complicated with pneumonia which resolved after 
antibiotic treatment. Anticoagulation with war-
farin was initiated, and on postoperative day 8, 
the patient was discharged to a local hospital for 
further management. On postoperative day 30, 
the follow-up was uneventful.
Another patient, a 76-year-old man with Stan-
ford type A AD, anticoagulated with dabigatran 
(2 × 110 mg/d; last intake on the day preceding 
the day of surgery) for paroxysmal AF was admit-
ted to our institution in May 2016 for emergency 
surgery. His other risk factors were stage 2 CKD 
and arterial hypertension. We confirmed the di-
agnosis of AAA and AD with computed tomog-
raphy, and the preoprative laboratory findings 
are presented in TABLE 1. Also in this patient, the 
bleeding risk was high (3 points in the Papworth 
Bleeding Risk Score).4
Immediate surgery was executed using the 
same protocol (time from hospital admission until 
admission to the operating room was 98 minutes, 
there was no delay due to dabigatran therapy). 
To the Editor The recent European Heart Rhythm 
Association (EHRA) practical guidelines on the 
use of non-vitamin-K oral anticoagulants in pa-
tients with nonvalvular AF recommend adminis-
tration of idarucizumab for life-threatening bleed-
ing or prior to emergency surgery in dabigatran-
-treated patients.1 At the end of 2015, idarucizum-
ab, a monoclonal antibody fragment that binds 
dabigatran with high affinity, was approved for 
use in Europe. In the context of the European 
guidelines,1 we would like to present our experi-
ence with the use of the specific reversal agent in 
everyday practice, indicating the important role 
of idarucizumab in the setting of surgery that 
cannot be delayed.
Dabigatran etexilate (dabigatran), a direct 
thrombin inhibitor, is commonly used for stroke 
prevention in patients with atrial fibrillation 
(AF),2 who can experience serious perioperative 
bleeding if the procedure is performed while on 
anticoagulation.
Acute aortic syndromes (AASs) are a common 
cause for emergency cardiac surgery associated 
with high mortality and morbidity. The REVERSE 
AD trial3 has shown that idarucizumab is effica-
cious in dabigatran reversal, and it was used in a 
single patient with aortic dissection (AD) in this 
trial. According to the study protocol, idarucizum-
ab was administered preopreatively. We used ida-
rucizumab intraoperatively in 2 dabigatran-treat-
ed patients with Stanford type A AAS.
An 83-year-old man with a history of ascend-
ing aortic aneurysm (AAA) complicated with AAS 
in form of Stanford type A intramural hematoma, 
was taking dabigatran due to AF (2 × 110 mg/d; 
last dose intake on the day of surgery). Comorbidi-
ties were chronic kidney disease (stage 3 CKD), ar-
terial hypertension, prior ischemic stroke, periph-
eral arterial disease, and peptic ulcer disease. The 
diagnosis was confirmed with contrast -enhanced 
computed tomography. Preoprative laboratory 
findings, including dabigatran concentrations 
based on dilute thrombin time, are presented in 
TABLE 1. According to the Papworth Bleeding Risk 
Score, the bleeding risk was high (4 points).4
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Our approach was slightly different, as a result 
of cardiac surgery-specific procedural character-
istics. During an open heart surgery, coagulation 
is blocked anyway with heparin, and internal CPB 
suction is used to prevent blood loss. The rationale 
behind the choice of the idarucizumab adminis-
tration timepoint was to provide the patient with 
dabigatran-free coagulation for as long postoper-
atively as possible. Dabigatran levels returned to 
normal in both cases. In the first patient, post-
operative drainage was low, and bleeding was as-
sessed as moderate—not more pronounced than 
in any other patient with AAS.
The important issue of necessary dabigatran 
treatment adjustment in individuals with renal 
failure warrants a comment, as both our patients 
suffered from CKD. The Cockcroft–Gault formula 
for creatinine clearace (CrCl) was employed in the 
RELY trial6 for the assessment of dabigatran eli-
gibility and dosing. In AF patients aged 80 years 
or older, it has been demonstrated that 15% were 
ineligible for dabigatran based on CrCl of less 
than 30 ml/min, but the same patients would 
have been eligible if the the Modification of Diet 
in Renal Disease (MDRD) formula had been ap-
plied for the calculation of estimated glomeru-
lar filtration rate (eGFR); for those younger than 
80 years, 5% would have received too high a dose 
of dabigatran.7 Thus, some patients (whose re-
nal function is assessed based on eGFR with the 
MDRD formula) probably receive dabigatran de-
spite excluding CKD or receive too high a dose. 
Furthermore, during CKD exacerbation, dabiga-
tran should be stopped if there is any suspicion 
that the patient might need urgent surgery (as 
in a patient with known severe aortic dilation). 
That nonwithstanding, our report demonstrates 
that salvage with idarucizumab is a bail-out op-
tion even in an dabigatran-overtreated individual 
with CKD exacerbation, who requires emergency 
cardiac surgery. No such option is available for pa-
tients treated with rivaroxaban or apixaban yet.
In our second patient, the fact of dabigatran in-
take was discovered after patient admission, dur-
ing the emergency anesthesia workup. Emergen-
cy medicine personnel should be trained to ob-
tain the information on dabigatran use and last 
intake from any patient with known AF and to 
pass this information to the tertiary care center. 
This approach is supported by the recent EHRA 
Upon opening of the pericardium, massive car-
diac tamponade was apparent; however, a supra-
coronary ascending aortic and hemiarch replace-
ment procedure was successfully performed. Ida-
rucizumab was administered after CPB termina-
tion (5 g IV, in 1 infusion of 5-minute duration), 
and the control level of dabigatran was 36 ng/ml 
in the operating room. Severe low cardiac output 
syndrome has developed upon CPB cessation. A 
total of 10 units of platelet concentrate, 3 units 
of fresh frozen plasma, and 2 units of packed red 
blood cells were administered in the operating 
room, before chest closure, and massive inotropic 
support was required (epinephrine, 1 µg/kg/min; 
norepinephrine, 0.83 µg/kg/min; dobutamine, 
10 µg/kg/min; milrinone, 0.42 µg/kg/min). Al-
though intraoperative transesophageal echocar-
diography revealed normal aortic valve function 
and appropriately de-aired left ventricle, severe 
cardiogenic shock developed and resistant hypo-
tension was observed. Mechanical circulatory sup-
port was not feasible. Despite the treatment, the 
patient expired directly following the end of the 
procedure, in the operating room, without any 
apparent bleeding.
Our current report demonstrates that idaruci-
zumab effectively reverses dabigatran in the set-
ting of emergency cardiac surgery for AAS in pa-
tients with high plasma drug levels. One patient 
had a completely favorable outcome, and the oth-
er died due to heart failure. However, no major 
bleeding was observed in any of the presented cas-
es, despite high preoperative bleeding risk (3–4 
points in the Papworth Bleeding Risk Score) and 
high preoperative levels of dabigatran. Only blood 
product transfusions were needed, but no activat-
ed prothrombin complex concentrate or recom-
bintant factor VII were necessary. Importantly, 
treatment with dabigatran did not delay any part 
of the cardiosurgical management, as idarucizum-
ab was readily available on site.
The REVERSE AD trial3 demonstrated that 
idarucizumab rapidly and completely reverses 
dabigatran levels (in most patients they dropped 
by 99% and remained low for at least 12 hours; 
in some cases, an increase in  dabigatran levels 
was observed after this time, probably second-
ary to drug redistribution from peripheral circu-
lation); however, in individuals requiring an op-
eration, it was administered before the surgery. 
TABLE 1 Preoperative laboratory findings in patients with acute aortic syndrome and receiving dabigatran treatment (reference ranges are given in 
brackets)
Patient, 
sex/age, 
y
RBC
(4.2–6.0 
×106/µl)
HGB  
(14.0–
18.0 g/dl)
HCT  
(40.0%–
54.0%)
PLT  
(140–440 
103/µl)
APTT  
(25.9–36.6 
sec)
INR 
(0.9–1.3)
Creatinine 
(62–106 
µmol/l)
eGFR (>60 ml/
min/1.73 m2 
Baseline 
dabigatran 
level, ng/ml
M/83 3.36 10.4 31.2 129 77.8 1.74 264 19 209
M/76 5.31 15.3 47.3 115 48.3 1.46 185 30 84
Dabigatran levels were measured using the Hemoclot thrombin inhibitor assay (HYPHEN BioMed, NeuvillesurOise, France), as described elsewhere.8  
Baseline dabigatran level (during dabigatran treatment): 61–143 ng/ml. 
Abbreviations: APTT, activated partial thromboplastin time; eGFR, estimated glomelural filtration rate; HCT, hematocrit; HGB, hemoglobin; INR, 
international normalized ratio; M, male; RBC, red blood cells; PLT, platelets
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guidelines.1 Idarucizumab should be available in 
any tertiary cardiac and trauma center, where 
patients treated with dabigatran are likely to be 
managed. All physicians should be made aware 
which centers have idarucizumab at their dispos-
al, and this information should be available at all 
times at any blood bank countrywide.
In conclusion, our report demonstrates that 
idarucizumab can facilitate successful cardiosur-
gical treatment with a satisfactory hemostasis in 
the setting of AAS, in a patient treated with dabig-
atran. We believe that in the setting of cardiac sur-
gery, the administration of idarucizumab intra-
operatively (not preoperatively) is safe. The dose 
of 5 g IV in a rapid infusion administered upon 
CPB cessation may be a good therapeutic choice.
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